Last updated on December 2016

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma


Brief description of study

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.

Clinical Study Identifier: NCT02742727

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Lin Yang, Ph.D

PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Suzhou, China
  Connect »